** Shares of drug developer Acadia Pharmaceuticals ACAD.O rise 34.2% to over 1-year high of $23.61
** U.S. District Court for the District of Delaware has ruled that India's Aurobindo Pharma infringes on two of Acadia Pharmaceuticals' patent claims
** The court has rejected Aurobindo's arguments that they are invalid
** The companies will meet to discuss next steps and submit a joint letter to the court within 21 days
** Acadia will provide an update on its revised stipulation regarding the patent claims within 7 days
** Companies must work together to redact sensitive information from the court's opinion and submit a proposed redacted version within 30 days
** Including session's move, stock up 28.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.